Celltrion provides one-stop solutions for the entire process of biopharmaceutical business from R&D to clinical trials, regulatory affairs, production and distribution. Read more

We strive to contribute to the improvement of patient welfare and access to healthcare by offering biologics. Established in 2018, Celltrion USA, headquartered in Jersey City, is committed to …

Celltrion, Inc. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and …

Celltrion, with an annual production capacity of 250,000L, is the largest manufacturer and exporter of biosimilars in Korea. Along with Remsima, Celltrion's first product, most products on the top …

Jan 15, 2025 · Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of …

Jan 15, 2025 · Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development strategy in the rigorous and cutting-edge field of …

Dec 18, 2024 · Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), for …

Aug 12, 2024 · Celltrion USA, Inc., (Celltrion USA) today announced its FDA-approved biosimilar adalimumab-aaty, has been added to the Costco member prescription program.

Celltrion is a leading global biopharmaceutical company that researches, develops and manufactures antibody biosimilars, new biologics and small molecule drugs. We have …

Bispecific or multispecific antibodies can efficiently modulate multiple targets at once. Celltrion is engaging in open innovation and joint development projects with global pharmaceutical …